Aa
Alinia as a monotherapy for some
Found this a few weeks back and don't remember anyone posting it. This may hold some , if only a little, hope for those not able to tolerate SOC at all. jerry
-- Data from a poster presentation, "Randomized, Double-Blind Placebo-
Controlled Trial of Nitazoxanide in the Treatment of Patients with
Chronic Hepatitis C Genotype 4" showed that nitazoxanide monotherapy
for 24 weeks did not produce adverse events significantly different
from that of a placebo and suggest that monotherapy with nitazoxanide
may be effective in achieving SVR in a limited subset of patients with
low viral load.
In this randomized, controlled study, 50 treatment-naïve patients with
chronic hepatitis C genotype 4 were randomized to receive one
nitazoxanide 500 mg tablet or a matching placebo tablet twice daily for 24 weeks. Baseline viral loads and other disease characteristics were similar between groups. Seven of 23 patients (34%) receiving
nitazoxanide monotherapy achieved undetectable serum HCV RNA after 24
weeks of therapy, compared with 0 of 24 patients receiving placebo
P=0.004). Four of these 7 treatment responders (4/23, or 17%) had a
SVR 24 weeks after completion of therapy. Patients not achieving
undetectable HCV RNA did not show significant reductions in viral load
or alanine aminotransferase (ALT) levels. Patients responding to
nitazoxanide treatment had lower viral loads at baseline. Adverse
events were typically mild to moderate and occurred with similar
frequency and severity between the nitazoxanide and placebo groups.
"The study demonstrated the safety of long-term nitazoxanide exposure
in patients with chronic hepatitis C. Importantly, this data suggests that
thiazolides have an interferon-like mechanism and as a class may have a
role as single agent therapy in some patients," said Dr. Emmet Keeffe,
chief medical officer for Romark and co-author of the study.
http://www.hepcaustralia.com.au/index.php/component/content/article/24-latest-news/611-romark-announces-presentation-of-new-data-for-nitazoxanide-in-chronic-hepatitis-c-at-easl-2008
-- Data from a poster presentation, "Randomized, Double-Blind Placebo-
Controlled Trial of Nitazoxanide in the Treatment of Patients with
Chronic Hepatitis C Genotype 4" showed that nitazoxanide monotherapy
for 24 weeks did not produce adverse events significantly different
from that of a placebo and suggest that monotherapy with nitazoxanide
may be effective in achieving SVR in a limited subset of patients with
low viral load.
In this randomized, controlled study, 50 treatment-naïve patients with
chronic hepatitis C genotype 4 were randomized to receive one
nitazoxanide 500 mg tablet or a matching placebo tablet twice daily for 24 weeks. Baseline viral loads and other disease characteristics were similar between groups. Seven of 23 patients (34%) receiving
nitazoxanide monotherapy achieved undetectable serum HCV RNA after 24
weeks of therapy, compared with 0 of 24 patients receiving placebo
P=0.004). Four of these 7 treatment responders (4/23, or 17%) had a
SVR 24 weeks after completion of therapy. Patients not achieving
undetectable HCV RNA did not show significant reductions in viral load
or alanine aminotransferase (ALT) levels. Patients responding to
nitazoxanide treatment had lower viral loads at baseline. Adverse
events were typically mild to moderate and occurred with similar
frequency and severity between the nitazoxanide and placebo groups.
"The study demonstrated the safety of long-term nitazoxanide exposure
in patients with chronic hepatitis C. Importantly, this data suggests that
thiazolides have an interferon-like mechanism and as a class may have a
role as single agent therapy in some patients," said Dr. Emmet Keeffe,
chief medical officer for Romark and co-author of the study.
http://www.hepcaustralia.com.au/index.php/component/content/article/24-latest-news/611-romark-announces-presentation-of-new-data-for-nitazoxanide-in-chronic-hepatitis-c-at-easl-2008
PS. Can't wait to see what data comes out of the trials currently going on for geno 1s...
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
